Computer-aided design of liposomal drugs: In silico prediction and experimental validation of drug candidates for liposomal remote loading.

Previously we have developed and statistically validated Quantitative Structure Property Relationship (QSPR) models that correlate drugs' structural, physical and chemical properties as well as experimental conditions with the relative efficiency of remote loading of drugs into liposomes (Cern et al., J. Control. Release 160 (2012) 147-157). Herein, these models have been used to virtually screen a large drug database to identify novel candidate molecules for liposomal drug delivery. Computational hits were considered for experimental validation based on their predicted remote loading efficiency as well as additional considerations such as availability, recommended dose and relevance to the disease. Three compounds were selected for experimental testing which were confirmed to be correctly classified by our previously reported QSPR models developed with Iterative Stochastic Elimination (ISE) and k-Nearest Neighbors (kNN) approaches. In addition, 10 new molecules with known liposome remote loading efficiency that were not used by us in QSPR model development were identified in the published literature and employed as an additional model validation set. The external accuracy of the models was found to be as high as 82% or 92%, depending on the model. This study presents the first successful application of QSPR models for the computer-model-driven design of liposomal drugs.

[1]  Bradley D Anderson,et al.  Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[2]  G. Betageri,et al.  Development and Stability Studies of Novel Liposomal Vancomycin Formulations , 2012, ISRN pharmaceutics.

[3]  M. Yeh,et al.  Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy , 2011, International journal of nanomedicine.

[4]  Gregory Gregoriadis,et al.  Liposome Technology, Volume I: Liposome Preparation and Related Techniques, Third Edition , 2006 .

[5]  Alexander Golbraikh,et al.  Quantitative structure-property relationship modeling of remote liposome loading of drugs. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[6]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[8]  Young Jik Kwon,et al.  "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Y. Barenholz,et al.  Liposomes: preparation, characterization, and preservation. , 2006 .

[10]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[11]  Yechezkel Barenholz,et al.  Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies. , 2003, Methods in enzymology.

[12]  Jean-Christophe Leroux,et al.  Development and physico-chemical characterization of a liposomal formulation of istaroxime. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  Liang Fang,et al.  Formulation and characterization of boanmycin-loaded liposomes prepared by pH gradient experimental design , 2012, Drug delivery.

[14]  Chan-Wha Kim,et al.  Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method , 2009 .

[15]  Y. Barenholz,et al.  Optimization and upscaling of doxorubicin-containing liposomes for clinical use. , 1990, Journal of pharmaceutical sciences.

[16]  E. Chan,et al.  Development of stealth liposome coencapsulating doxorubicin and fluoxetine , 2011, Journal of liposome research.

[17]  Y. Barenholz Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Hitoshi Sasaki,et al.  Fluorescence investigation of the retinal delivery of hydrophilic compounds via liposomal eyedrops. , 2011, Biological & pharmaceutical bulletin.

[19]  K A Pappa,et al.  The clinical development of mupirocin. , 1990, Journal of the American Academy of Dermatology.

[20]  S. Clerc,et al.  Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. , 1995, Biochimica et biophysica acta.

[21]  Ola. M. Abdallah RP-HPLC Determination of Three Anti-Hyperlipidemic Drugs in Spiked Human Plasma and in Dosage Forms , 2011 .

[22]  J. Li,et al.  In vitro and in vivo evaluation of sanguinarine liposomes prepared by a remote loading method with three different ammonium salts. , 2011, Die Pharmazie.

[23]  E. Azzopardi,et al.  The enhanced permeability retention effect: a new paradigm for drug targeting in infection. , 2013, The Journal of antimicrobial chemotherapy.

[24]  Takuya Fujisawa,et al.  Edaravone-loaded liposomes for retinal protection against oxidative stress-induced retinal damage. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  Y. Barenholz,et al.  Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. , 1989, Biochimica et biophysica acta.

[26]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[27]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[28]  Qiang Yu,et al.  Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  Xiaoju Zhou,et al.  Novel liposomal gefitinib (L-GEF) formulations. , 2012, Anticancer research.

[30]  Gert Storm,et al.  Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Yechezkel Barenholz,et al.  Relevancy of Drug Loading to Liposomal Formulation Therapeutic Efficacy , 2003, Journal of liposome research.

[32]  Amiram Goldblum,et al.  Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. , 2009, Journal of controlled release : official journal of the Controlled Release Society.